• Trials show benefit of ‘on demand’ use of AZ’ asthma inhaler pharmatimes
    May 24, 2018
    The trials tested the inhaler in place of current reliever therapy, a short-acting beta2-agonist (SABA), also taken as needed, and as an alternative to regular maintenance controller therapy (twice-daily budesonide, an inhaled corticosteroid, ICS) plus SA
PharmaSources Customer Service